| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.13 | 0.006 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.006 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.006 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 0.006 |